Teva Pharmaceutical Industries Limited (TEVA) and Lundbeck Inc. Release: TEMPO Extension Study Further Demonstrates the Benefits of Azilect(R) in Early Parkinson's Disease Patients
8/5/2010 10:49:12 AM
JERUSALEM & VALBY, Denmark--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) and H. Lundbeck A/S (Lundbeck) today announced newly published long-term data on Azilect® (rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson’s disease (PD) and further demonstrate the benefits obtained with early treatment initiation. The data was published in the June 2010 issue of the International Journal of Neuroscience.
comments powered by